13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839209
Total reported value
$3.8B
$3.8B
3 檔
38.9%
As reported in its official Q1 2025 Form 13F filing, Darwin Global Management, Ltd.'s tracked investment portfolio stood at $3.8B with 3 total positions.
In Q1 2025, Darwin Global Management, Ltd. adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 12 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 82.08% | -50.42% | +18.81% | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 16.81% | — | +384.08% | |
| 3 | ALLO | Allogene Therapeutics Inc | Stock-Other | 1.11% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | — | NEW | New buy |
| 2 | NTLA | Intellia Therapeutics Inc | — | EXIT | Sold out |
| 3 | VRNA | Verona Pharma PLC - Adr | — | NEW | New buy |
| 4 | XLRN | Acceleron Pharma Inc | — | EXIT | Sold out |
| 5 | FATE | Fate Therapeutics Inc | — | EXIT | Sold out |
| 6 | BBIO | Bridgebio Pharma Inc | — | EXIT | Sold out |
| 7 | BEAM | Beam Therapeutics Inc | — | EXIT | Sold out |
| 8 | ALLO | Allogene Therapeutics Inc | — | NEW | New buy |
| 9 | ✓ | Verve Therapeutics Inc | — | EXIT | Sold out |
| 10 | INBXUSD | Inhibrx Inc | — | EXIT | Sold out |
| 11 | EPIEUR | Essa Pharma Inc | — | EXIT | Sold out |
| 12 | KROS | Keros Therapeutics Inc | — | EXIT | Sold out |
| 13 | ACRS | Aclaris Therapeutics Inc | — | EXIT | Sold out |
| 14 | RLAY | Relay Therapeutics Inc | — | EXIT | Sold out |
| 15 | GBIOGBX | Generation Bio Co | — | EXIT | Sold out |
According to official SEC Form 13F filings, Darwin Global Management, Ltd. reported a total U.S. public equity portfolio value of $3.8B across 3 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, VRNA, ALLO) accounted for 38.9% of total reported equity market value during Q1 2025.
Top New Position Initiated
INSM
市值: $1.2B
Top Position Liquidated / Trimmed
NTLA
前期市值: $301.1M
During Q1 2025, Darwin Global Management, Ltd.'s top holdings by market value included INSM (82.1%)、VRNA (16.8%)、ALLO (1.1%). The largest single position, INSM, represented 82.1% of total portfolio value.
In Q1 2025, Darwin Global Management, Ltd. made 15 total portfolio adjustments, initiating 3 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.